Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT02442297
What this trial is testing

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

Who this might be right for
Brain Tumor, RecurrentBrain Tumor, Refractory
Baylor College of Medicine 10
Early research (Phase 1)Ended earlyNCT04314843
What this trial is testing

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Large B-cell Lymphoma
Kite, A Gilead Company 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06429150
What this trial is testing

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Who this might be right for
Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT03393936
What this trial is testing

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Shanghai PerHum Therapeutics Co., Ltd. 66
Early research (Phase 1)Active Not RecruitingNCT03696030
What this trial is testing

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Who this might be right for
Malignant NeoplasmMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the Leptomeninges+2 more
City of Hope Medical Center 24
Early research (Phase 1)Active Not RecruitingNCT05757700
What this trial is testing

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaLarge B-cell LymphomaDLBCL, Nos Genetic Subtypes+2 more
Memorial Sloan Kettering Cancer Center 30
Not applicableUnknownNCT04780529
What this trial is testing

CART Therapy in Digestive System Tumors

Who this might be right for
Malignant Neoplasms of Digestive Organs
Innovative Cellular Therapeutics Co., Ltd. 20
Testing effectiveness (Phase 2)UnknownNCT04499339
What this trial is testing

A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wuerzburg University Hospital 38
Early research (Phase 1)Active Not RecruitingNCT06757881
What this trial is testing

IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma

Who this might be right for
HCC
Shanghai Zhongshan Hospital 3
Early research (Phase 1)Not Yet RecruitingNCT07316907
What this trial is testing

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

Who this might be right for
Hematologic MalignanciesLymphoma
YANRU WANG 12
Early research (Phase 1)Ended earlyNCT03323944
What this trial is testing

CAR T Cell Immunotherapy for Pancreatic Cancer

Who this might be right for
Pancreatic CancerCancer of the Pancreas
University of Pennsylvania 54
Testing effectiveness (Phase 2)Looking for participantsNCT06897930
What this trial is testing

Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Who this might be right for
Lupus Erythematosus, Systemic
AstraZeneca 150
Early research (Phase 1)Temporarily pausedNCT06197672
What this trial is testing

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia
Huda Salman 30
Early research (Phase 1)Looking for participantsNCT05225363
What this trial is testing

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Who this might be right for
Platinum-Resistant Ovarian Carcinoma
City of Hope Medical Center 33
Early research (Phase 1)Study completedNCT02107963
What this trial is testing

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Who this might be right for
SarcomaOsteosarcomaNeuroblastoma+1 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Looking for participantsNCT07467863
What this trial is testing

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Who this might be right for
Non-Small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech 48
Early research (Phase 1)Ended earlyNCT04025216
What this trial is testing

CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Who this might be right for
Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more
Kite, A Gilead Company 16
Early research (Phase 1)Looking for participantsNCT06478693
What this trial is testing

MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Who this might be right for
Hepatocellular Carcinoma
Myeloid Therapeutics 70
Early research (Phase 1)Study completedNCT05022849
What this trial is testing

JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 15
Early research (Phase 1)Active Not RecruitingNCT03190278
What this trial is testing

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Cellectis S.A. 29
Next Page